# Resmed Moat

Status: published. Policy: company-analysis-1.

Resmed demonstrates product innovation, global distribution, growing demand and manufacturing efficiencies, but the passages do not establish a durable advantage over competitors. Connected workflows could create switching friction; brand-specific customer dependence remains unproven. Pricing power is mixed: fiscal 2024 average selling prices increased, while recent profitability improvements primarily reflected efficiencies. Reimbursement constraints, competition, alternative therapies and realized safety costs qualify durability without establishing a weak competitive position.

## intangible_assets

Current product-development capabilities and distribution across more than 140 countries support competitive relevance. Recent device, mask and FDA-cleared software launches demonstrate innovation, but superior customer outcomes, protected economics and persistent differentiation versus competitors are not established.

Durability: An established distribution footprint and continued launches support continuity of capability, but the evidence cannot establish the duration of an economic advantage.

Risks: Multibrand referral channels, competing devices, alternative therapies and a substantial Philips return could weaken differentiation. Astral safety expenses demonstrate an actual product-quality cost.

Invalidation: The candidate advantage would be undermined by sustained loss of device and mask unit demand to competing products, repeated safety failures, or price concessions required to maintain sales despite continued launches.

Competitors: Philips BV, Fisher & Paykel Healthcare Corporation Limited, DeVilbiss Healthcare, Apex Medical Corporation
## switching_costs

Remote monitoring, device-setting tools and clinical workflow software provide potential operational integration benefits. The passages do not demonstrate that Resmed customers face material migration costs or remain because of those costs. The explicit substantial-integration disclosure concerns prospective customers' existing software and therefore also describes a barrier to winning business.

Durability: Workflow integration could support persistence, but migration expense, renewals and brand retention are undisclosed. MatrixCare's completed sale narrows the software portfolio relevant to the current assessment.

Risks: Multibrand channels, customer rental termination options and superior competing software could limit dependence. Recurring service obligations establish ongoing delivery rather than proven retention.

Invalidation: The switching-cost hypothesis would be undermined by customers moving monitoring or billing workflows between vendors with little disruption, declining renewals, or device substitution without losing clinically useful workflow functionality.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm) · 2026-08-13
- [https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/rmd-20260331.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/rmd-20260331.htm) · 2026-05-01
- [https://www.sec.gov/Archives/edgar/data/943819/000094381926000080/rmd-20261001.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381926000080/rmd-20261001.htm) · 2026-10-01
- [https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm) · 2025-08-08
- [https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/rmd-20240630.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/rmd-20240630.htm) · 2024-08-09
- [https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/rmd-20251231.htm](https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/rmd-20251231.htm) · 2026-01-30
- [https://www.sec.gov/Archives/edgar/data/943819/000119312526354154/d292919dex991.htm](https://www.sec.gov/Archives/edgar/data/943819/000119312526354154/d292919dex991.htm) · 2026-08-17
- [https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732dex991.htm](https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732dex991.htm) · 2026-08-06

[JSON](https://beanvest.com/stock/rmd/moat.json)